Answers are grounded in this paper and cite their sources.
Clinical assessment shows improvement in skin laxity and facial contour in ten female patients, highlighting the lifting effect of poly-l-lactic acid.
Poly-L-lactic acid (PLLA) is a biocompatible, absorbable, immunologically inert polymer that induces neocollagenesis. In the late 1990s, it began to be used as a bio-stimulator not only for the treatment of skin aging and other causes of facial lipoatrophy, but also as cosmetic indications in non-facial areas to improve skin quality. About two years ago, a new presentation of poly-L-lactic acid was launched in Brazil under the name RennovaElleva®. The product RennovaElleva® has been approved by ANVISA for the treatment of skin laxity, leading to the restoration of facial volume and tissue repositioning on the face and body. Each vial contains 210 mg of poly-L-lactic acid (PLLA), carboxymethylcellulose (132 mg) and mannitol (178 mg). It comes in the form of a lyophilized powder that should be reconstituted in 16 ml of final diluent volume. In this article, we describe the results obtained using the vector application technique, which aimed at improving skin laxity and facial contour with a lifting effect in ten female patients, with two sessions spaced 45 days apart. In addition to the clinical results achieved at 3 and 6 months after the end of treatment, safety and efficacy outcomes were analyzed over this period. We also discuss the distinctive characteristics of this new presentation.
No takes yet. Share an insight, caveat, or question.
Cunha et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: